Single-dose Actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Ongology Group

E. S. Petrilli, L. B. Twiggs, J. A. Blessing, N. N H Teng, S. Curry

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The Gynecologic Oncology Group (GOG) conducted a prospective trial of single-dose Actinomycin-D (ACT-D) given intravenously (IV) at 1.25 mg/m2 every 2 weeks to patients with nonmetastatic gestational trophoblastic disease (NMGTD) in order to determine the efficacy of pulse scheduling and the frequency and severity of associated toxicity. Of 31 evaluable patients, 29 (94%) achieved remission after receiving a median of four courses of therapy. Two patients who failed to respond to pulse therapy were subsequently cured by alternative treatment. There were 93 toxic events in 133 cycles of therapy. Ninety-two percent of adverse effects were graded as mild or moderate, and 8% were graded as severe. No life-threatening toxicity occurred. Although single-dose ACT-D efficacy and toxicity is comparable to conventional therapy for NMGTD, the advantages of easier administration, greater patient convenience, and improved cost-effectiveness make it superior to other alternatives. On this basis it is recommended as the treatment of choice for NMGTD.

Original languageEnglish
Pages (from-to)2173-2176
Number of pages4
JournalCancer
Volume60
Issue number9
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Gestational Trophoblastic Disease
Dactinomycin
Therapeutics
Poisons
Cost-Benefit Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Petrilli, E. S., Twiggs, L. B., Blessing, J. A., Teng, N. N. H., & Curry, S. (1987). Single-dose Actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Ongology Group. Cancer, 60(9), 2173-2176.

Single-dose Actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Ongology Group. / Petrilli, E. S.; Twiggs, L. B.; Blessing, J. A.; Teng, N. N H; Curry, S.

In: Cancer, Vol. 60, No. 9, 01.01.1987, p. 2173-2176.

Research output: Contribution to journalArticle

Petrilli, E. S. ; Twiggs, L. B. ; Blessing, J. A. ; Teng, N. N H ; Curry, S. / Single-dose Actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Ongology Group. In: Cancer. 1987 ; Vol. 60, No. 9. pp. 2173-2176.
@article{7b566023c63149eebecc6cabbec78221,
title = "Single-dose Actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Ongology Group",
abstract = "The Gynecologic Oncology Group (GOG) conducted a prospective trial of single-dose Actinomycin-D (ACT-D) given intravenously (IV) at 1.25 mg/m2 every 2 weeks to patients with nonmetastatic gestational trophoblastic disease (NMGTD) in order to determine the efficacy of pulse scheduling and the frequency and severity of associated toxicity. Of 31 evaluable patients, 29 (94{\%}) achieved remission after receiving a median of four courses of therapy. Two patients who failed to respond to pulse therapy were subsequently cured by alternative treatment. There were 93 toxic events in 133 cycles of therapy. Ninety-two percent of adverse effects were graded as mild or moderate, and 8{\%} were graded as severe. No life-threatening toxicity occurred. Although single-dose ACT-D efficacy and toxicity is comparable to conventional therapy for NMGTD, the advantages of easier administration, greater patient convenience, and improved cost-effectiveness make it superior to other alternatives. On this basis it is recommended as the treatment of choice for NMGTD.",
author = "Petrilli, {E. S.} and Twiggs, {L. B.} and Blessing, {J. A.} and Teng, {N. N H} and S. Curry",
year = "1987",
month = "1",
day = "1",
language = "English",
volume = "60",
pages = "2173--2176",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Single-dose Actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Ongology Group

AU - Petrilli, E. S.

AU - Twiggs, L. B.

AU - Blessing, J. A.

AU - Teng, N. N H

AU - Curry, S.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - The Gynecologic Oncology Group (GOG) conducted a prospective trial of single-dose Actinomycin-D (ACT-D) given intravenously (IV) at 1.25 mg/m2 every 2 weeks to patients with nonmetastatic gestational trophoblastic disease (NMGTD) in order to determine the efficacy of pulse scheduling and the frequency and severity of associated toxicity. Of 31 evaluable patients, 29 (94%) achieved remission after receiving a median of four courses of therapy. Two patients who failed to respond to pulse therapy were subsequently cured by alternative treatment. There were 93 toxic events in 133 cycles of therapy. Ninety-two percent of adverse effects were graded as mild or moderate, and 8% were graded as severe. No life-threatening toxicity occurred. Although single-dose ACT-D efficacy and toxicity is comparable to conventional therapy for NMGTD, the advantages of easier administration, greater patient convenience, and improved cost-effectiveness make it superior to other alternatives. On this basis it is recommended as the treatment of choice for NMGTD.

AB - The Gynecologic Oncology Group (GOG) conducted a prospective trial of single-dose Actinomycin-D (ACT-D) given intravenously (IV) at 1.25 mg/m2 every 2 weeks to patients with nonmetastatic gestational trophoblastic disease (NMGTD) in order to determine the efficacy of pulse scheduling and the frequency and severity of associated toxicity. Of 31 evaluable patients, 29 (94%) achieved remission after receiving a median of four courses of therapy. Two patients who failed to respond to pulse therapy were subsequently cured by alternative treatment. There were 93 toxic events in 133 cycles of therapy. Ninety-two percent of adverse effects were graded as mild or moderate, and 8% were graded as severe. No life-threatening toxicity occurred. Although single-dose ACT-D efficacy and toxicity is comparable to conventional therapy for NMGTD, the advantages of easier administration, greater patient convenience, and improved cost-effectiveness make it superior to other alternatives. On this basis it is recommended as the treatment of choice for NMGTD.

UR - http://www.scopus.com/inward/record.url?scp=0023193279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023193279&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 2173

EP - 2176

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -